MARUAN HIJAZI VEGA

Dr. MARUAN HIJAZI VEGA

Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Castille-Leon, Spain
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HGHenry Gerdes
Henry Gerdes
PCPedro Casado
Pedro Casado
ADArran Dokal
Arran Dokal
MARUAN HIJAZI VEGAMARUAN HIJAZI VEGA
MARUAN HIJAZI VEGA
NANosheen Akhtar
Nosheen Akhtar
PCPedro Rodriguez Cutillas
Pedro Rodriguez Cutillas
Artificial intelligence and machine learning (ML) promise to transform cancer therapies by accurately predicting the most appropriate therapies to treat individual patients. Here, we present an approach, named Drug Ranking Using ML (DRUML), which uses omics data to produce ordered lists of >400 drugs based on their anti-proliferative efficacy in cancer cells. To reduce noise and increase predictive robustness, instead of individual features, DRUML uses internally normalized distance metrics of drug response as features for ML model generation. DRUML is trained using in-house proteomics and phosphoproteomics data derived from 48 cell lines, and it is verified with data comprised of 53 cellular models from 12 independent laboratories. We show that DRUML predicts drug responses in independent verification datasets with low error (mean squared error < 0.1 and mean Spearman’s rank 0.7). In addition, we demonstrate that DRUML predictions of cytarabine sensitivity in clinical leukemia samples are prognostic of patient survival (Log rankp < 0.005). Our results indicate that DRUML accurately ranks anti-cancer drugs by their efficacy across a wide range of pathologies.

20 January 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MARUAN HIJAZI VEGAMARUAN HIJAZI VEGA
MARUAN HIJAZI VEGA
RSRyan Smith
Ryan Smith
VRVinothini Rajeeve
Vinothini Rajeeve
CBConrad Bessant
Conrad Bessant
PCPedro Rodriguez Cutillas
Pedro Rodriguez Cutillas

1 June 2020 in Cell
Verified
Journal Article
Closed access
PWPing-Pui Wong
Ping-Pui Wong
JMJose M. Munoz-Felix
Jose M. Munoz-Felix
MARUAN HIJAZI VEGAMARUAN HIJAZI VEGA
MARUAN HIJAZI VEGA
HKHyojin Kim
Hyojin Kim
SRStephen D. Robinson
Stephen D. Robinson
KHKairbaan Hodivala-Dilke
Kairbaan Hodivala-Dilke

23 December 2016 in Proteomics
Verified
Journal Article
Closed access
PDF file
PCPedro Casado
Pedro Casado
MARUAN HIJAZI VEGAMARUAN HIJAZI VEGA
MARUAN HIJAZI VEGA
DBDavid Britton
David Britton
PCPedro Rodriguez Cutillas
Pedro Rodriguez Cutillas

1 May 2020 in Cell Systems
Verified
Journal Article
Open access
BIBrandon M. Invergo
Brandon M. Invergo
BPBorgthor Petursson
Borgthor Petursson
NANosheen Akhtar
Nosheen Akhtar
DBDavid Bradley
David Bradley
GGGirolamo Giudice
Girolamo Giudice
PBPedro Beltrao
Pedro Beltrao
Complex networks of regulatory relationships between protein kinases comprise a major component of intracellular signaling. Although many kinase-kinase regulatory relationships have been described in detail, these tend to be limited to well-studied kinases whereas the majority of possible relationships remains unexplored. Here, we implement a data-driven, supervised machine learning method to predict human kinase-kinase regulatory relationships and whether they have activating or inhibiting effects. We incorporate high-throughput data, kinase specificity profiles, and structural information to produce our predictions. The results successfully recapitulate previously annotated regulatory relationships and can reconstruct known signaling pathways from the ground up. The full network of predictions is relatively sparse, with the vast majority of relationships assigned low probabilities. However, it nevertheless suggests denser modes of inter-kinase regulation than normally considered in intracellular signaling research. A record of this paper's transparent peer review process is included in the Supplemental Information.

19 April 2022 in Science Signaling
Verified
Journal Article
Closed access
FPFederico Pedicona
Federico Pedicona
PCPedro Casado
Pedro Casado
MARUAN HIJAZI VEGAMARUAN HIJAZI VEGA
MARUAN HIJAZI VEGA
JGJohn G. Gribben
John G. Gribben
KRKevin Rouault-Pierre
Kevin Rouault-Pierre
PCPedro Rodriguez Cutillas
Pedro Rodriguez Cutillas
Most tumor types either fail to respond or become resistant to kinase inhibitors, often because of compensatory prosurvival pathways in the cancer cell’s broader signaling circuitry. Here, we found that intrinsic resistance to kinase inhibitors in cultured primary acute myeloid leukemia (AML) cells may be overcome by reshaping kinase networks into topologies that confer drug sensitivity. We identified several antagonists of chromatin-modifying enzymes that sensitized AML cell lines to kinase inhibitors. Of these, we confirmed that inhibitors of the lysine-specific demethylase (LSD1; also known as KDM1A) rewired kinase signaling in AML cells in a way that increased the activity of the kinase MEK and that broadly suppressed the activity of other kinases and feedback loops. As a result, AML cell lines and about half of primary human AML samples were primed for sensitivity to the MEK inhibitor trametinib. Primary human cells with KRAS mutations and those with high MEK pathway activity were the best responders to sequential treatment with LSD1 inhibitors then trametinib, whereas those with NRAS mutations and high mTOR activity were poor responders. Overall, our study reveals the MEK pathway as a mechanism of resistance to LSD1 inhibitors in AML and shows a way to modulate kinase network circuitry to potentially overcome therapeutic resistance to kinase inhibitors.